

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Pillar Invest Corp</u> (Last) (First) (Middle) PILLAR INVEST OFFSHORE SAL STARCO CTR, BLOC B, 3RD FLOOR, OMAR DAOUK STREET (Street) BEIRUT M8 2020-3313 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>IDERA PHARMACEUTICALS, INC. [IDRA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/27/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/27/2020		S		15,000	D	\$1.77	3,284,224 ⁽¹⁾	I	See Footnote ⁽¹⁾
Common Stock	01/28/2020		S		12,532	D	\$1.762 ⁽²⁾	3,271,692 ⁽³⁾⁽⁵⁾	I	See Footnote ⁽³⁾⁽⁵⁾
Common Stock	01/29/2020		S		17,250	D	\$1.7645 ⁽⁴⁾	3,254,442 ⁽⁵⁾⁽⁶⁾	I	See Footnote ⁽⁵⁾⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)					

1. Name and Address of Reporting Person* <u>Pillar Invest Corp</u> (Last) (First) (Middle) PILLAR INVEST OFFSHORE SAL STARCO CTR, BLOC B, 3RD FLOOR, OMAR DAOUK STREET (Street) BEIRUT M8 2020-3313 (City) (State) (Zip)

1. Name and Address of Reporting Person* <u>Pillar Pharmaceuticals I LP</u> (Last) (First) (Middle) PILLAR INVEST OFFSHORE SAL STARCO CTR, BLOC B, 3RD FLOOR, OMAR DAOUK STREET (Street) BEIRUT M8 2020-3313 (City) (State) (Zip)
--

1. Name and Address of Reporting Person*

[Pillar Pharmaceuticals II, L.P.](#)

(Last) (First) (Middle)

PILLAR INVEST OFFSHORE SAL, STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)

BEIRUT M8 2020-3313

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Pillar Pharmaceuticals III, L.P.](#)

(Last) (First) (Middle)

PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR OMAR DAOUK STREET

(Street)

BEIRUT M8 2020-3313

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Pillar Pharmaceuticals IV, L.P.](#)

(Last) (First) (Middle)

PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)

BEIRUT M8 2020-3313

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Pillar Pharmaceuticals V LP](#)

(Last) (First) (Middle)

PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)

BEIRUT M8 2020-3313

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Pillar Pharmaceuticals 6, L.P.](#)

(Last) (First) (Middle)

PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)

BEIRUT M8 2020-3313

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Pillar Partners Foundation, L.P.](#)

(Last) (First) (Middle)

PILLAR INVEST OFFSHORE SAL STARCO CTR
BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)

BEIRUT M8 2020-3313

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>Umari Abude</u>		
(Last)	(First)	(Middle)
PILLAR INVEST OFFSHORE SAL STARCO CTR, BLOC B, 3RD FLOOR, OMAR DAOUK STREET		
(Street)		
BEIRUT	M8	2020-3313
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>ZEIN YOUSSEF EL</u>		
(Last)	(First)	(Middle)
PILLAR INVEST OFFSHORE SAL, STARCO CTR, BLOC B, 3RD FLOOR, OMAR DAOUK STREET		
(Street)		
BEIRUT	M8	2020-3313
(City)	(State)	(Zip)

Explanation of Responses:

- Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"). Pillar Invest Corporation ("Pillar GP") disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I. Following this transaction, Pillar I owns directly 21,100 shares of common stock of the Issuer.
- The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from \$1.76-\$1.77. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- Shares sold by Pillar Pharmaceuticals II, L.P. ("Pillar II"). Pillar Invest Corporation ("Pillar GP") disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. Following this transaction, Pillar II owns directly 20,820 shares of common stock of the Issuer.
- The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from \$1.76-\$1.7707. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- Shares sold by Pillar Pharmaceuticals III, L.P. ("Pillar III"). Pillar Invest Corporation ("Pillar GP") disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar III and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar III. Following the transactions on 1/28/20 and 1/29/20, Pillar III owns directly 29,998 shares of common stock of the Issuer.
- Shares sold by Pillar Pharmaceuticals V, L.P. ("Pillar V"). Pillar Invest Corporation ("Pillar GP") disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar V and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar V. Following this transaction, Pillar V owns directly 25,000 shares of common stock of the Issuer.

Remarks:

Pillar Invest Corporation, /s/
Youssef El Zein, Authorized
Person 02/26/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.